In addition, we found that the Myl9 levels in the plasma of IBD patients, especially UC patients, were strongly correlated with the disease severity, suggesting that plasma Myl9 levels are a useful new biomarker of the disease activity of IBD. This evidence concerns the gene MYL9 and inflammatory bowel disease.